Uloric Lawsuits For Cardiovascular Deaths, Heart Problems, Strokes, Kidney Failure
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Uloric (febuxostat), prescribed for the management of chronic gout since 2009, has been associated with increased risk of cardiovascular deaths, heart problems, and strokes. In turn, Uloric lawsuits have been filed against Takeda Pharmaceuticals, the manufacturer of Uloric, alleging this drug company failed to adequately warn doctors and patients about these Uloric side effects.
In February 2019 the FDA required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, for the Uloric drug label in order to better inform doctors and patients about the increased risks of heart-related deaths as well as deaths from all causes associated with the use of Uloric.
Uloric heart-related side effects include:
- Cardiovascular Death (CV Death or CVD)
- Sudden Cardiac Arrest or Sudden Cardiac Death (SCD)
- Heart Failure (HF)
- Heart Attack or Myocardial Infarction (MI)
- Stroke or Cerebrovascular Accident (CVA)
- Unstable Angina with Urgent Coronary Revascularization
Some other serious Uloric side effects are:
- Acute Renal Failure (ARF)
- Acute Kidney Injury (AKI)
Our law firm is investigating possible Uloric lawsuits where patients have suffered Uloric side effects.
We encourage you to submit a Uloric Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Uloric
According to a recent medical journal article, acute renal failure (ARF), or kidney failure, is reported as an adverse drug reaction 5.7 times more frequently with Uloric (febuxostat) than with other urate-lowering therapy (ULT) gout drugs, and 3.3 times more often with allopurinol. This is some important new Uloric drug safety information from our perspective.
To read more of this article, click below:
This article, “Acute Kidney Injury Associated With Febuxostat and Allopurinol — A Post-Marketing Study”, was published by the Arthritis Research & Therapy medical journal in November 2019. The new Uloric drug safety information in that article is summarized in this excerpt:
In the present study, we detected a disproportionality signal for [acute renal failure (ARF)] and the ULTs [Uloric (febuxostat)] and allopurinol. The presence of this signal was confirmed in a variety of sensitivity analyses (i.e., when [Uloric (febuxostat)] and allopurinol were the only suspected drugs, when we used other [Xanthine oxydase (XO)] inhibitors as the comparator or when known nephrotoxic drugs were excluded).
…. Until the present case/non-case study, the risk of [acute kidney injury (AKI)] associated with allopurinol and [Uloric (febuxostat)] had been underestimated.
We will continue to monitor the FDA and review medical journals for any significant developments concerning this new Uloric drug safety information about acute kidney injury (AKI) and acute renal failure (ARF).
Our law firm is investigating possible Uloric lawsuits where patients have suffered Uloric side effects.[Read article in full at original source]
Earlier articles about Uloric by attorney Tom Lamb on the Side Effects Blog:
- Uloric Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
- Uloric Warning: Avoid Uloric If Prior Myocardial Infarction, Stroke, Or Unstable Angina
- Uloric Lawsuits Follow Recent FDA Warnings About Heart-Related Deaths And Side Effects
- February 2019: Uloric “Black-Box Warning” For Heart-Related Deaths, Cardiovascular Side Effects
- Uloric Recall Discussed By FDA Advisory Committees In January 2019
- Will FDA Order Uloric Recall Requested In June 2018 By Public Citizen
- Gout Drug Uloric Has Higher Risk Of Death vs. Allopurinol: CARES Trial
- November 2017 FDA Alert: Uloric May Increase Heart-Related Deaths Risk